Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$377K, compared with $141K a year earlier.
Context
- Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -367.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (64K) USD
- Year-over-year change
- -133.0%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (64K) | -133.0% |
| FY2024 | 2024-12-31 | 194K | +424.3% |
| FY2023 | 2023-12-31 | 37K | +190.2% |
| FY2022 | 2022-12-31 | (41K) | — |
Accumulated OCI vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 Accumulated OCI of -$377K is the lowest of the 8 companies compared; the peer median is $22K.
- Its year-over-year change of -367.4% is the lowest of 7, against a peer median of -82.3%.
- Accumulated OCI amounts to 0.1% of total assets for ZBIO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $9.68M | -91.7% | -56.2% | 84.2% | |
| Sep 2026 | $519K | -64.2% | -5.0% | 0.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $100K | -72.8% | — | 0.0% |
| Mar 2026 | $22K | -94.9% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$81K | +11.0% | — | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | -$146K | -100.0% | — | 0.1% |
| Mar 2026 | -$377K | -367.4% | — | 0.1% | |
| Peer median (excluding ZBIO) | $22K | -82.3% | -30.6% | 0.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.